Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.

Masahiro Takada,Shigeru Imoto,Takanori Ishida,Yoshinori Ito,Hiroji Iwata,Norikazu Masuda,Hirofumi Mukai,Shigehira Saji,Takafumi Ikeda,Hironori Haga,Toshiaki Saeki,Kenjiro Aogi,Tomoharu Sugie,Takayuki Ueno,Shinji Ohno,Hiroshi Ishiguro,Chizuko Kanbayashi,Takeshi Miyamoto,Yasuo Ohashi,Masakazu Toi

Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.

2020

532Background: Estimation of risk of recurrence is critical for adjuvant therapy decision making in patients with primary breast cancer. The POTENT trial examined outcomes associated with standard ...

Keywords:

Physical therapy
Oncology
Breast cancer
primary breast cancer
Internal medicine
exploratory analysis
HER2 negative
in patient
Adjuvant therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations